Liquid Biopsy Market Is Growing At A CAGR of 28.9% from 2017 to 2023 | Latest Research Report
Pune, Maharashtra, India, November 19 2020 (Wiredrelease) Allied Analytics –:UPDATE AVAILABLE ON-DEMAND
The report on the global liquid biopsy market highlights that the market is expected to reach $634 million in 2016, and is estimated to reach at $3,805 million by 2023, registering a CAGR of 28.9% from 2017 to 2023. The report offers the current market size and forecasts along with Porter’s Five Forces analysis to help market players, stakeholders, startups, and investors to determine the current scenario and take further steps for the future. Drivers and opportunities for highest revenue generating and fastest growing segments would help in tapping into specific segment to achieve growth. Moreover, regional analysis would assist in expansion strategies for the market players and startups.
North America was the highest contributor in the liquid biopsy market in 2016; however, Asia-Pacific is anticipated to witness a highest growth rate throughout the forecast period.
Liquid biopsy tests prove to be an easy and non-invasive method to access to molecular information about the tumor genome. Moreover, these tests facilitate early detection of cancer recurrence and characterization of tumor dynamics. Safety and efficiency of cancer treatment is improved by the use of these tests, owing to their ability to characterize new lesions, implement apt therapeutic targets, and predict the treatment outcome.
Download Free Report Sample @ https://www.alliedmarketresearch.com/request-sample/1891
The advantages of implementing liquid biopsy over conventional methods of solid tissue biopsy are expected to boost the growth of the market. The advantages of liquid biopsies, such as minimally invasiveness and metastatic relapse evaluation, are expected to increase the demand for these tests. Furthermore, the increase in disposable income among cancer patients, surge in prevalence of cancer cases, and patient preference for minimally invasive therapies are anticipated to fuel the market growth. Rise in healthcare expenditure in the developing countries, such as India and China, and use of liquid biopsy tests to treat rare cancers are expected to present multiple opportunities for market growth. However, this growth is restricted, owing to alternatives to liquid biopsies and unclear reimbursement & regulation scenario.
Reagent was the highest revenue contributor in 2016, and is anticipated to continue this trend in the future. The requirement of reagents to execute liquid biopsy tests and their applicability are expected to boost the growth of this segment.
Inquire before buying @ https://www.alliedmarketresearch.com/purchase-enquiry/1891
Lung cancer dominates the cancer by type segment of liquid biopsy market. The U.S. Food and Drug Administration (FDA) has also approved a liquid biopsy companion diagnostic test called cobas EGFR mutation test v2 to identify patients with metastatic non-small cell lung cancer (NSCLC) In addition, the growth in prevalence of lung cancer has contributed to provide lucrative opportunities in the market.
In 2016, North America accounted for highest contribution to the total revenue generated, owing to the high prevalence rate of cancer and high adoption rate of novel liquid biopsy tests. However, Asia-Pacific is expected to witness the highest CAGR during the analysis period, attributable to rise in disposable income, increase in government initiatives to modernize healthcare infrastructure, and rise in healthcare expenditure.
Access Full Report @ https://www.alliedmarketresearch.com/liquid-biopsy-market
The Major Key Players Are:
Biocept, Inc., Qiagen, F. Hoffmann-La Roche AG , Bio-Rad Laboratories Inc., Myriad Genetics , Janssen Diagnostics, LLC., Trovagene Inc., Guardant Health Inc., GRAIL, and MDX Health SA.
Key Findings of the Liquid Biopsy Market:
• The government & academic research center segment is projected to grow at the highest rate during the analysis period.
• Hospital & laboratory segment was the highest revenue-generating segment, and is expected to continue its dominance in future.
• North America dominated global liquid biopsy market, and is projected to grow at a CAGR of 28.1%.
• China is expected to grow at the highest CAGR of 34.1% in Asia-Pacific region.
• The instruments segment is anticipated to grow at the highest CAGR of 29.8% during the forecast period.
Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
This content has been published by Allied Analytics company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at email@example.com.